

Olivier Deckmyn

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3156636/olivier-deckmyn-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

26
papers

1,598
citations

12
h-index

27
g-index

27
ext. papers

1,770
ext. citations

4.1
avg. IF

3.2
L-index

| # | Paper | IF | Citations |
|----|--|------|-----------|
| 26 | Validation of the performance of A1HPV6, a triage blood test for the early diagnosis and prognosis of SARS-CoV-2 infection. 2022 , | | 1 |
| 25 | Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.. <i>Biomedicines</i> , 2022 , 10, | 4.8 | 1 |
| 24 | Possible Conflict of Interest statement.. <i>Clinical Gastroenterology and Hepatology</i> , 2022 , | 6.9 | 0 |
| 23 | External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B 2022 , 1, 604-617 | | 0 |
| 22 | External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV. <i>JHEP Reports</i> , 2021 , 3, 100298 | 10.3 | 3 |
| 21 | Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 54, 952-966 | 6.1 | 3 |
| 20 | Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. <i>PLoS ONE</i> , 2020 , 15, e0242306 | 3.7 | 4 |
| 19 | Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes. <i>European Journal of Gastroenterology and Hepatology</i> , 2020 , 32, 998-1007 | 2.2 | 5 |
| 18 | External validation of an algorithm combining multi-analyte blood tests (FibroTest-LCR1-LCR2) to identify subjects at risk of hepatocellular carcinoma in patients with chronic liver disease. <i>GastroHep</i> , 2019 , 1, 146-153 | 1 | 2 |
| 17 | The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2019 , 31, 393-402 | 2.2 | 8 |
| 16 | LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 308-320 | 6.1 | 8 |
| 15 | Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. <i>European Journal of Gastroenterology and Hepatology</i> , 2018 , 30, 569-577 ² | | 13 |
| 14 | Impact of steatosis and inflammation definitions on the performance of NASH tests. <i>European Journal of Gastroenterology and Hepatology</i> , 2018 , 30, 384-391 | 2.2 | 7 |
| 13 | Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 1117-1127 | 6.1 | 14 |
| 12 | Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 877-89 | 6.1 | 54 |
| 11 | Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison. <i>PLoS ONE</i> , 2016 , 11, e0163276 | 3.7 | 24 |
| 10 | Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity. <i>BMJ Open</i> , 2015 , 5, e010017 | 3 | 9 |

| | | | |
|---|---|------|------|
| 9 | Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest [®]) and elastography (FibroScan [®]). <i>Journal of Hepatology</i> , 2014 , 61, 994-1003 | 13.4 | 36 |
| 8 | Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest [®]) and transient elastography (FibroScan [®]). <i>Journal of Hepatology</i> , 2014 , 60, 706-14 | 13.4 | 85 |
| 7 | Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2013 , 59, 675-83 | 13.4 | 115 |
| 6 | Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population. <i>Journal of Hepatology</i> , 2012 , 57, 541-8 | 13.4 | 52 |
| 5 | Real time identification of drug-induced liver injury (DILI) through daily screening of ALT results: a prospective pilot cohort study. <i>PLoS ONE</i> , 2012 , 7, e42418 | 3.7 | 14 |
| 4 | Ranking hepatologists: which HirschWh-index to prevent the "e-crise de foi-e"?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011 , 35, 375-86 | 2.4 | 21 |
| 3 | Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age. <i>BMC Gastroenterology</i> , 2011 , 11, 39 | 3 | 53 |
| 2 | Hirsch index and truth survival in clinical research. <i>PLoS ONE</i> , 2010 , 5, e12044 | 3.7 | 7 |
| 1 | Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfecting patients. The Multivirc Group. <i>Hepatology</i> , 1999 , 30, 1054-8 | 11.2 | 1058 |